African Burkitt's lymphoma. History, biology, clinical features, and treatment. | Read by QxMD (original) (raw)
Historical Article
Journal Article
Review
Dennis Burkitt's first description of the African tumor that is now known by his name appeared in 1958. In the brief intervening span of 32 years, this lymphoma has provided an extraordinarily valuable paradigm that has afforded insights into topics that encompass the entire discipline of oncology. These include the origins of lymphoid neoplasms at epidemiological, cellular, and molecular levels, and the efficacy of chemotherapy in rapidly progressive, widely disseminated lymphomas. In addition, epidemiological considerations led to the discovery of a new virus, the Epstein-Barr virus, which has proved to be an important human pathogen. This virus probably plays a pathogenetic role in several neoplastic diseases, including the lymphoproliferative syndromes associated with inherited and acquired immunodeficiency. Small, noncleaved cell lymphoma is the latest histological designation of the category of lymphomas that includes Burkitt's lymphoma. This tumor, which is biologically heterogeneous, has become notorious because of its high incidence in individuals infected with the human immunodeficiency virus, which is providing a second, potentially fertile model for the exploration of the pathogenesis of lymphoid neoplasms. Already, enough is known of the pathogenesis of Burkitt's lymphoma to permit the first tentative steps toward the development of novel therapeutic approaches directed toward the molecular genetic abnormalities associated with the neoplasm. In this article, the history, biology, clinical features, and treatment of African Burkitt's lymphoma are reviewed.
Full text links
We have located links that may give you full text access.
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-
2024
by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our
and
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app